Taysha Gene Therapies Profit Margin

Taysha Gene Therapies (TSHA) currently reports a profit margin of -1738.4% as of March 2026. That compares with -1201.08% in the prior-year period — down 44.7% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Taysha Gene Therapies's profit margin history and peer comparisons.

Taysha Gene Therapies's profit margin decreased from -1201.08% to -1738.4% — a 44.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taysha Gene Therapies's profit margin of -1738.4% is lower than the Healthcare sector average of 14.34%. That is roughly 12218.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Taysha Gene Therapies's current -1738.4% should be judged against Healthcare norms (sector average: 14.34%) and against TSHA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1738.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Taysha Gene Therapies, and consider following TSHA for alerts when major investors trade the stock.